Published in J Clin Oncol on April 15, 2004
The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol (2010) 2.07
Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A (2012) 1.46
Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother (2014) 1.17
New insights into IL-12-mediated tumor suppression. Cell Death Differ (2014) 1.09
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther (2009) 1.03
Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther (2011) 1.03
Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther (2009) 1.01
Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging (2005) 1.01
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med (2010) 0.96
IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One (2011) 0.94
Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci (2009) 0.92
Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther (2010) 0.92
Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther (2012) 0.91
Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One (2012) 0.90
In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother (2015) 0.90
Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther (2009) 0.89
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol (2015) 0.88
Gene therapy of liver cancer. World J Gastroenterol (2006) 0.86
Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol (2011) 0.86
Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J Virol (2009) 0.86
Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol (2006) 0.85
Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy. Mol Cancer (2009) 0.85
Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84
New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs (2010) 0.83
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology (2011) 0.82
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Mol Cancer Ther (2016) 0.79
Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
The liberation of CD44 intracellular domain modulates adenoviral vector transgene expression. J Biol Chem (2012) 0.77
Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer. Mol Ther Oncolytics (2015) 0.77
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer (2005) 0.76
Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases. J Transl Med (2010) 0.75
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev (2016) 0.75
Endoscopic ultrasound: an overview of its role in current clinical practice. Australas J Ultrasound Med (2015) 0.75
[Indications for pancreatic biopsy. Uncommon, but increasingly more important]. Pathologe (2005) 0.75
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet (2007) 13.62
Genome assembly comparison identifies structural variants in the human genome. Nat Genet (2006) 6.93
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 2.76
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA (2005) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol (2003) 2.12
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology (2003) 1.90
Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol (2012) 1.86
Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol (2007) 1.84
SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity (2006) 1.79
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients. Crit Care Med (2011) 1.70
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther (2013) 1.62
Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (2012) 1.61
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.61
Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J (2004) 1.57
Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl (2011) 1.54
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Clinical outcome of subcentimeter non-small cell lung cancer after surgical resection: single institution experience of 105 patients. J Surg Oncol (2014) 1.43
[Association of age, inflammatory markers and subclinical atherosclerosis in subjects free from cardiovascular disease]. Med Clin (Barc) (2008) 1.40
Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer (2013) 1.40
Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther (2009) 1.37
The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol (2011) 1.36
MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett (2011) 1.34
Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res (2009) 1.33
Sexual and drug use behavior among women who have sex with both women and men: results of a population-based survey. Am J Public Health (2002) 1.27
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology (2004) 1.24
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol (2005) 1.23
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail (2010) 1.22
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther (2010) 1.21
Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology (2013) 1.21
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther (2003) 1.17
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16
HIV-related risk behavior among Hispanic immigrant men in a population-based household survey in low-income neighborhoods of northern California. Sex Transm Dis (2005) 1.15
Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther (2005) 1.15
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology (2011) 1.14
N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc Natl Acad Sci U S A (2012) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13
Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology (2011) 1.11
Cholinergic-dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol (2003) 1.10
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol (2011) 1.10
The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects. Hum Mol Genet (2009) 1.09
Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology (2004) 1.09
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res (2006) 1.08